Beta DrugsNSE:BETA -3.02%88 PEG Ratio is 4.68 as of Jul. 06, 2026, which is 86% above its 10-year median of 2.51. GuruFocus rates NSE:BETA with a GF Score™ of 88/100 and a GF Value™ of ₹1,970.72 (Fairly Valued). The stock has 6 warning signs investors should review. Among 348 Drug Manufacturers companies, Beta Drugs ranks worse than 78.16% on this metric.
PE Ratio without NRI / 5-Year EBITDA Growth Rate*
PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Beta Drugs's PE Ratio without NRI is 120.63. Beta Drugs's 5-Year EBITDA growth rate is 25.80%. Therefore, Beta Drugs's PEG Ratio for today is 4.68.
* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
The historical rank and industry rank for Beta Drugs's PEG Ratio or its related term are showing as below:
NSE:BETA'
s PEG Ratio Range Over the Past 10 Years
Min: 2.25 Med: 2.51 Max: 4.69
Current: 4.68
During the past 13 years, Beta Drugs's highest PEG Ratio was 4.69. The lowest was 2.25. And the median was 2.51.
NSE:BETA's PEG Ratio is ranked worse than 78.16% of 348
companies
in the Drug Manufacturers industry
Industry Median: 1.7
vs NSE:BETA: 4.68
Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.
Beta Drugs (NSE:BETA) PEG Ratio Explanation
To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.
Beta Drugs PEG Ratio Related Terms
Beta Drugs PEG Ratio Historical Data
* Premium members only.
The historical data trend for Beta Drugs's PEG Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs PEG Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's PEG Ratio distribution charts can be found below:
* The bar in red indicates where Beta Drugs's PEG Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.
Beta Drugs (NSE:BETA) has a PEG Ratio of 4.68 as of Jul. 06, 2026. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Beta Drugs and its competitors. This is 86% above median its historical median of 2.51. Over the past decade, Beta Drugs' PEG Ratio has ranged from 2.25 to 4.69. According to the industry distribution chart, Beta Drugs ranks #272 out of 348 companies in the Drug Manufacturers industry, placing it in the top 78.2%.
Is Beta Drugs' PEG Ratio too high?
Beta Drugs' current PEG Ratio of 4.68 is 86% above median its 10-year median of 2.51. Over the past 10 years, this metric has ranged from a low of 2.25 to a high of 4.69. The Drug Manufacturers industry median PEG Ratio is 1.70. Beta Drugs' value of 4.68 is 175.3% above this industry median. Based on the distribution chart, Beta Drugs ranks #272 out of 348 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Beta Drugs has a GF Score™ of 88/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' PEG Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #272 out of 348 companies for PEG Ratio. This places Beta Drugs in the lower half of its industry. The industry median PEG Ratio is 1.70. Beta Drugs' value of 4.68 is 175.3% above this benchmark. Historically, Beta Drugs' own PEG Ratio has ranged from 2.25 to 4.69 over the past decade. While the company's 10-year median is 2.51 vs. the industry median of 1.70, Beta Drugs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PEG Ratio for a Drug Manufacturers company?
The median PEG Ratio among Drug Manufacturers companies is 1.70, based on 348 companies in the industry. Companies in the top quartile (top 25%) have a PEG Ratio significantly above this median, while those in the bottom quartile fall well below. However, PEG Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current PEG Ratio of 4.68 is 175.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PEG Ratio mean?
A high PEG Ratio can signal that a stock is expensive relative to its fundamentals. Price-earnings to growth ratio is the ratio of price-earnings to a company's earnings growth rate. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median PEG Ratio is 1.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current PEG Ratio is 4.68, which is 86% above median its own 10-year median of 2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,970.72, compared to a current price of ₹2,090.50 — trading 6.1% above its estimated fair value. The current PEG Ratio is 4.68, which is 86% above median its 10-year median of 2.51 and 175.3% above the Drug Manufacturers industry median of 1.70. Beta Drugs' overall GF Score™ is 88/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PEG Ratio calculated?
PEG Ratio is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current PEG Ratio is 4.68 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,090.50 is trading 6.1% above its estimated GF Value™ of ₹1,970.72.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
PEG Ratio: 4.68 (86% above median its 10-year median of 2.51)
GF Value™: ₹1,970.72 vs. price of ₹2,090.50 (6.1% above fair value)
Industry Position: 175.3% above the Drug Manufacturers median (#272 of 348)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
88GF Score
Get the complete analysis for NSE:BETA
PEG Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
